Conversations around controlling the $4.4 trillion in health care costs veer towards the 5% of the population who are most ill and "who account for 50% of all health care spending," many of whom have "multiple chronic conditions," according to Harvard Business Review. Similarly, 25% of the annual costs stem from 3% of individuals previously unrecognized or invisible as high-risk patients, thus demanding ways to identify risk factors earlier, solutions for lowering overall costs, and ultimately saving lives.
Transparency Matters
Molecular You (MY), led by CEO Jim Kean, is not only creating solutions for this healthcare visibility gap but also pioneering an entirely new category of healthcare that uses cutting-edge biomarker-driven risk profiling software to increase transparency. Kean explains, "I very rarely have seen a blank ecosystem area, but there is not a holistic biomarker-driven risk predictive system out there." The MY magic lies in its ability to identify potential risk factors and help people and their providers better understand their health.
The inability to spot, predict, and manage health events within 12 months costs the system $550 billion annually. MY tackles that problem by providing unprecedented insight into the pre-symptomatic, pre-claims health of individuals and populations.
Multi-biomarker Driven
Even though genetics can help identify risk factors, Molecular You instead uses hundreds of proteome and metabolome biomarkers to provide holistic and accurate information regarding a person's wellness. MY started with an impressive 250 tested biomarkers and is increasing to over 800 by 2024.
Their multi-biomarker test utilizes AI and machine learning to compute unique risk scores across 26 biological areas. Molecular You's advanced, low-cost testing can illuminate risk factors for several conditions, allowing for early identification and tailored interventions and treatments, thereby lowering long-term costs.
Pioneering SaMD
The Molecular You pioneers, including David Wishart, Christoph Borchers, Rob Fraser, and Gene Shkolnikov, have built a platform that regulatory authorities can consider a "Software as a Medical Device" (SaMD). A SaMD is a platform that can be used like other traditional medical devices (e.g., a pacemaker), which identifies risks, diagnoses, and monitors medical conditions. These important state-of-the-art SaMDs provide individuals and their healthcare professionals with important information that can minimize illness and disease and save lives, not to mention cut costs significantly.
While approval of a novel method can take many years, MY's strategic approach will help them bypass the lengthy and costly approval process, which positions them as an economical, visionary solution in this healthcare landscape.
Managing significant costs in the healthcare industry, driven mainly by a small percentage of the population, is essential. Molecular You is addressing that problem with a truly revolutionary approach that offers a view of wellness never available before, a view so bright you better wear shades.
